GlassScriptPhysician profile
Kenneth R Luckay
NPI 1770572331
$3,224.77
in general payments reported to CMS, 2019-2025
26 companies · $373 in 2025
The $373 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $355 · 2021: $793 · 2022: $353 · 2023: $248 · 2024: $720 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,341.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $572.76 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $394.58 | 2021-2025 | Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $289.55 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $281.51 | 2019-2023 | Wegovy |
| Lilly USA, LLC | $215.40 | 2020-2024 | Zepbound, Jardiance, Mounjaro |
| Abbott Laboratories | $159.05 | 2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $129.44 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $124.07 | 2020-2021 | |
| Pfizer INC. | $112.20 | 2019-2023 | |
| Avanir Pharmaceuticals, INC. | $109.42 | 2021 | |
| Biodelivery Sciences International, INC. | $97.51 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $96.92 | 2022 | |
| Abbvie INC. | $89.57 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.63 | 2019 | |
| Idorsia Pharmaceuticals US INC | $77.01 | 2023 | Quviviq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $57.36 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $46.70 | 2022 | |
| Bausch Health US, LLC | $43.54 | 2022 | |
| Lundbeck LLC | $39.88 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $39.17 | 2019 | |
| Shire North American Group INC | $35.54 | 2019 | |
| Acella Pharmaceuticals, LLC | $34.15 | 2022-2025 | NP Thyroid 60 |
| Halozyme INC | $33.16 | 2023 | |
| Antares Pharma, INC. | $27.97 | 2020-2024 | Xyosted |
| Kaleo, INC. | $16.21 | 2019 | |
| Verity Pharmaceuticals INC. | $14.47 | 2024 | Tlando |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Luckay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.